Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1985 Jun;85(2):447–456. doi: 10.1111/j.1476-5381.1985.tb08881.x

Selective effects of thiol reagents on the binding sites for imipramine and neurotransmitter amines in the rat brain.

R Biassoni, A Vaccari
PMCID: PMC1916610  PMID: 2992663

Abstract

The action of the antithyroid drugs methimazole (MMI) and propylthiouracil (PTU) on the binding of [3H]-imipramine, [3H]-5-hydroxytryptamine [3H]-5-HT) (to 5-HT1-receptors) and [3H]-spiperone (to 5-HT2-, D2-receptors) of rat brain membranes has been examined. The synaptosomal uptake of [3H]-5-HT was also studied. Micromolar concentrations of the disulphide bond reducing agents MMI, PTU, dithiothreitol (DTT) and mercaptoethanol increased both the binding of [3H]-imipramine and the uptake of [3H]-5-HT. In contrast, they decreased the number of 5-HT1-receptors, and did not affect 5-HT2-and D2-sites. Reaction with membrane-bound sulphydryl (SH) groups by micromolar concentrations of N-ethylmaleimide (NEM), hydroxymercuribenzoic acid (PCMB), or Ellman's reagent (DTNB) decreased the binding of [3H]-imipramine, the number of 5-HT1-receptors, and the uptake of [3H]-5-HT. Millimolar concentrations of NEM were necessary in order to decrease partially 5-HT2- and D2-receptors. The effects of NEM on imipramine recognition sites and on the uptake of 5-HT could be prevented by DTT; protection was not obtained in other receptor systems. Three groups of receptors have been, thus, postulated, based upon their different sensitivity towards alterations in membrane [disulphide bridges in equilibrium SH] equilibrium: Group I, including imipramine recognition sites and the uptake system for 5-HT; Group II, including 5-HT1-receptors; Group III, including 5-HT2-and D2-receptors.

Full text

PDF
447

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbaccia M. L., Gandolfi O., Chuang D. M., Costa E. Modulation of neuronal serotonin uptake by a putative endogenous ligand of imipramine recognition sites. Proc Natl Acad Sci U S A. 1983 Aug;80(16):5134–5138. doi: 10.1073/pnas.80.16.5134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bennett J. P., Jr, Snyder S. H. Serotonin and lysergic acid diethylamide binding in rat brain membranes: relationship to postsynaptic serotonin receptors. Mol Pharmacol. 1976 May;12(3):373–389. [PubMed] [Google Scholar]
  3. Davis A. Molecular aspects of the imipramine 'receptor'. Experientia. 1984 Aug 15;40(8):783–794. doi: 10.1007/BF01951960. [DOI] [PubMed] [Google Scholar]
  4. Davis A. Temperature-sensitive conformational changes in [3H]imipramine binding sites and the involvement of sulphur-containing bonds. Eur J Pharmacol. 1984 Jul 13;102(2):341–347. doi: 10.1016/0014-2999(84)90266-8. [DOI] [PubMed] [Google Scholar]
  5. Dumbrille-Ross A., Morris J., Davis A., Tang S. W. Temperature-sensitive reversible loss of [3H]imipramine binding sites: evidence suggesting different conformational states. Eur J Pharmacol. 1983 Aug 5;91(4):383–389. doi: 10.1016/0014-2999(83)90162-0. [DOI] [PubMed] [Google Scholar]
  6. Fillion G., Fillion M. P. Transitional states of the neuronal serotonergic site. Eur J Pharmacol. 1980 Jul 11;65(1):109–112. doi: 10.1016/0014-2999(80)90218-6. [DOI] [PubMed] [Google Scholar]
  7. Freedman S. B., Poat J. A., Woodruff G. N. Influence of sodium and sulphydryl groups on [3H]sulpiride binding sites in rat striatal membranes. J Neurochem. 1982 May;38(5):1459–1465. doi: 10.1111/j.1471-4159.1982.tb07926.x. [DOI] [PubMed] [Google Scholar]
  8. Fuxe K., Calza L., Benfenati F., Zini I., Agnati L. F. Quantitative autoradiographic localization of [3H]imipramine binding sites in the brain of the rat: relationship to ascending 5-hydroxytryptamine neuron systems. Proc Natl Acad Sci U S A. 1983 Jun;80(12):3836–3840. doi: 10.1073/pnas.80.12.3836. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hamon M., Goetz C., Gozlan H. Reciprocal modulations of central 5-HT receptors by GTP and cations. Adv Biochem Psychopharmacol. 1983;37:349–359. [PubMed] [Google Scholar]
  10. Hartley E. J., Seeman P. Development of receptors for dopamine and noradrenaline in rat brain. Eur J Pharmacol. 1983 Aug 5;91(4):391–397. doi: 10.1016/0014-2999(83)90163-2. [DOI] [PubMed] [Google Scholar]
  11. Heron D. S., Shinitzky M., Hershkowitz M., Samuel D. Lipid fluidity markedly modulates the binding of serotonin to mouse brain membranes. Proc Natl Acad Sci U S A. 1980 Dec;77(12):7463–7467. doi: 10.1073/pnas.77.12.7463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kienzl E., Riederer P., Jellinger K., Wesemann W. Transitional states of central serotonin receptors in Parkinson's disease. J Neural Transm. 1981;51(1-2):113–122. doi: 10.1007/BF01664009. [DOI] [PubMed] [Google Scholar]
  13. Kinnier W. J., Chuang D. M., Gwynn G., Costa E. Characteristics and regulation of high affinity [3H] imipramine binding to rat hippocampal membranes. Neuropharmacology. 1981 May;20(5):411–419. doi: 10.1016/0028-3908(81)90170-2. [DOI] [PubMed] [Google Scholar]
  14. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  15. Langer S. Z., Moret C., Raisman R., Dubocovich M. L., Briley M. High-affinity [3H]imipramine binding in rat hypothalamus: association with uptake of serotonin but not of norepinephrine. Science. 1980 Dec 5;210(4474):1133–1135. doi: 10.1126/science.7444441. [DOI] [PubMed] [Google Scholar]
  16. Le Fur G., Phan T., Burgevin M. C., Flamier A., Mitrani N., Marquis F., Jozefczak C., Uzan A. A subacute treatment of L-methionine induces an increase in the number of [3H]spiperone binding sites in the striatum of the rat. Life Sci. 1983 May 16;32(20):2321–2328. doi: 10.1016/0024-3205(83)90761-0. [DOI] [PubMed] [Google Scholar]
  17. List S. J., Seeman P. Resolution of dopamine and serotonin receptor components of [3H]spiperone binding to rat brain regions. Proc Natl Acad Sci U S A. 1981 Apr;78(4):2620–2624. doi: 10.1073/pnas.78.4.2620. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Palkovits M., Raisman R., Briley M., Langer S. Z. Regional distribution of [3H]imipramine binding in rat brain. Brain Res. 1981 Apr 6;210(1-2):493–498. doi: 10.1016/0006-8993(81)90933-1. [DOI] [PubMed] [Google Scholar]
  19. Paul S. M., Rehavi M., Rice K. C., Ittah Y., Skolnick P. Does high affinity [3H] imipramine binding label serotonin reuptake sites in brain and platelet? Life Sci. 1981 Jun 15;28(24):2753–2760. doi: 10.1016/0024-3205(81)90177-6. [DOI] [PubMed] [Google Scholar]
  20. Peterson L. L., Bartfai T. In vitro and in vivo inhibition of [3H]imipramine binding by cadmium. Eur J Pharmacol. 1983 Jun 3;90(2-3):289–292. doi: 10.1016/0014-2999(83)90252-2. [DOI] [PubMed] [Google Scholar]
  21. Raisman R., Briley M. S., Langer S. Z. Specific tricyclic antidepressant binding sites in rat brain characterised by high-affinity 3H-imipramine binding. Eur J Pharmacol. 1980 Feb;61(4):373–380. doi: 10.1016/0014-2999(80)90076-x. [DOI] [PubMed] [Google Scholar]
  22. Raiteri M., Del Carmine R., Bertollini A., Levi G. Effect of sympathomimetic amines on the synaptosomal transport of noradrenaline, dopamine and 5-hydroxytryptamine. Eur J Pharmacol. 1977 Jan 21;41(2):133–143. doi: 10.1016/0014-2999(77)90202-3. [DOI] [PubMed] [Google Scholar]
  23. Suen E. T., Stefanini E., Clement-Cormier Y. C. Evidence for essential thiol groups and disulfide bonds in agonist and antagonist binding to the dopamine receptor. Biochem Biophys Res Commun. 1980 Sep 30;96(2):953–960. doi: 10.1016/0006-291x(80)91447-3. [DOI] [PubMed] [Google Scholar]
  24. Tamir H., Liu K. P. On the nature of the interaction between serotonin and serotonin binding protein: effect of nucleotides, ions, and sulfhydryl reagents. J Neurochem. 1982 Jan;38(1):135–141. doi: 10.1111/j.1471-4159.1982.tb10864.x. [DOI] [PubMed] [Google Scholar]
  25. Vaccari A. Effects of neonatal antithyroid treatment on brain [3H]-imipramine binding sites. Br J Pharmacol. 1985 Mar;84(3):773–778. doi: 10.1111/j.1476-5381.1985.tb16160.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Wennogle L. P., Beer B., Meyerson L. R. Human platelet imipramine recognition sites: biochemical and pharmacological characterization. Pharmacol Biochem Behav. 1981 Dec;15(6):975–982. doi: 10.1016/0091-3057(81)90065-4. [DOI] [PubMed] [Google Scholar]
  27. Woodruff G. N., Holden-Dye L., Senior K., Poat J. A. Functional dopamine receptors in the brain. Neuropharmacology. 1984 Feb;23(2B):243–246. doi: 10.1016/0028-3908(84)90065-0. [DOI] [PubMed] [Google Scholar]
  28. Zivin J. A., Waud D. R. How to analyze binding, enzyme and uptake data: the simplest case, a single phase. Life Sci. 1982 Apr 26;30(17):1407–1422. doi: 10.1016/0024-3205(82)90554-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES